Last reviewed · How we verify
NCT05809284: CARPERS
Determining the Mechanisms of Loss of CAR T Cell Persistence
trial in Acute Lymphoblastic Leukemia With Failed Remission in 50 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 18 October 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 3 locations across United Kingdom |
Conditions studied
- Acute Lymphoblastic Leukemia With Failed Remission — all drugs for Acute Lymphoblastic Leukemia With Failed Remission →
- Acute Lymphoblastic Leukemia Not Having Achieved Remission — all drugs for Acute Lymphoblastic Leukemia Not Having Achieved Remission →
- Acute Lymphoblastic Leukemia, Pediatric — all drugs for Acute Lymphoblastic Leukemia, Pediatric →
- Acute Lymphoblastic Leukemia, Adult — all drugs for Acute Lymphoblastic Leukemia, Adult →
Sponsor
University College, London
Who can join
Under 25, any sex, with Acute Lymphoblastic Leukemia With Failed Remission or Acute Lymphoblastic Leukemia Not Having Achieved Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05809284
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lymphoblastic Leukemia With Failed Remission
Currently open trials in the same condition.
- NCT05292664 — Venetoclax Basket Trial for High Risk Hematologic Malignancies · Phase 1 · recruiting
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05809284 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 23 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809284.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing